Community-acquired pleuropneumonia in children: Bacteriological and therapeutic challenges

La Tunisie Medicale
|October 6, 2016
PubMed

Insights

Community-acquired pleuropneumonia (CPP) in children is serious, with incidence doubling from 2004-2012. Staphylococcus aureus was the primary pathogen, necessitating a broad-spectrum antibiotic strategy and limited pleural drainage.

Area of Science:

  • Pediatric Infectious Diseases
  • Pulmonology
  • Critical Care Medicine

Background:

  • Community-acquired pleuropneumonia (CPP) is a severe pediatric complication of pneumonia, associated with significant morbidity and mortality.
  • The incidence of pediatric CPP has notably increased, doubling between 2004 and 2012.

Purpose of the Study:

  • To investigate the clinical and paraclinical characteristics of pediatric CPP.
  • To establish an effective therapeutic strategy for managing CPP in children.

Main Methods:

  • A retrospective study analyzed medical records of 164 children hospitalized for CPP between 2004 and 2012.
  • Data included patient demographics, clinical presentation, diagnostic examinations, and treatment outcomes.
  • Statistical analysis was performed using Epi-Info 6.

Main Results:

  • Fever, cough, and dyspnea were the predominant symptoms.
  • Pleural fluid analysis was the most effective diagnostic method, yielding bacterial confirmation in 44.5% of cases.
  • Staphylococcus aureus (59%) was the leading pathogen, particularly in younger infants and severe cases, followed by Streptococcus pneumoniae (26%).

Conclusions:

  • Bacteriological confirmation of CPP remains challenging, with pleural fluid aspiration being crucial.
  • Staphylococcus aureus and Streptococcus pneumoniae are the primary causative agents.
  • A therapeutic approach involving broad-spectrum intravenous antibiotics and judicious use of pleural drainage is recommended.

Related Concept Videos

Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
1.1K
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
999
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
1.2K
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
581
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
349
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
626